MRIN-UPH

Overview

Mochtar Riady Institute for Nanotechnology.

Mochtar Riady Institute for Nanotechnology (MRIN) didirikan pada tahun 2006 sebagai bagian dari Lippo Health and Medical Program, yang terdiri dari Fakultas Kedokteran UPH, Bioteknologi UPH, Siloam Hospitals, dan Mochtar Riady Comprehensive Cancer Center (MRCCC).

MRIN meresponi pandemi global dengan meneliti Covid-19. Hingga hari ini, MRIN diakui sebagai institusi penelitian swasta satu-satunya di Indonesia yang berpartisipasi dalam mengirimkan genom ke GISAID, dengan total 17 urutan asam nukleat di bulan Mei 2020 dan Januari 2021.

Untuk mengetahui lebih lanjut tentang MRIN, kunjungi website MRIN

MRIN.

Visi

  • Untuk menjadi pusat penelitian yang diakui secara internasional di bidang nanomedicines yang berfokus pada onkologi.
  • Meningkatkan kualitas dan kompetensi bangsa di bidang kedokteran nano melalui pendidikan yang bermutu dan penemuan ilmiah.
  • Untuk mendorong penelitian dan pendidikan di bidang kedokteran nano melalui kemitraan dan kolaborasi penelitian interdisipliner.

Misi

  • Untuk melakukan riset inovatif pada pencegahan kanker dan pemahaman baru tentang penyebab kanker, diagnosis dini, pengendalian dan penyembuhan kanker.

Kabar Terbaru.

RNA/DNA Isolation Lab.

Laboratorium ini merupakan tempat untuk mengekstrak asam nukleat (DNA / RNA) dari sumber hayati (seperti darah / jaringan). Lab ini didukung oleh Biological Safety Cabinet level 2, mesin sentrifugal dengan berbagai kapasitas, dan sonikator.

SNP Lab.

Laboratorium Polimorfisme Nukleotida Tunggal (SNP) menyediakan keahlian dalam eksperimen DNA dan genetika molekuler yang melakukan penelitian tentang kesehatan dan penyakit pada tingkat populasi. Lab ini didukung oleh alat Genetic Analyzer, mesin PCR, elektroforesis DNA dan sistem pencitraan molekulernya, serta alat Spektrofotometri. Biospesimen seperti DNA, RNA, darah, jaringan dan urin disimpan di ruangan ini pada dua suhu rendah (minus 20 derajat) dan empat buah freezer suhu ultra rendah (minus 80 derajat).

Pathology Lab.

Laboratorium Patologi di MRIN menyediakan alat pengolah jaringan yang mendukung untuk diagnostik histologi atau histopatologi seperti; Tissue Processor dan Tissue Parafin Embedding Station. Biosafety Cabinet kelas 2 juga disediakan sebagai perlindungan pribadi di lab ini untuk persiapan jaringan atau prosedur pewarnaan.

Genomic Lab.

Laboratorium Genomik berfokus pada analisis genom dan DNA untuk mendukung penelitian kanker. Terdapat beberapa instrumen lab di Genomic Lab seperti Laminar flow cabinet, Mesin thermocycler / PCR, Peralatan elektroforesis, dan alat-alat lainnya.

Flow Cytometry Lab.

Flow Cytometry adalah metode laboratorium yang digunakan untuk mendeteksi, mengidentifikasi, dan menghitung sel tertentu. Metode ini juga dapat mengidentifikasi komponen tertentu di dalam sel.

Cell Culture Lab.

Laboratorium kultur sel memiliki kapasitas untuk kultur sel mamalia rutin (pemeliharaan dan sub-kultur) dan untuk eksperimen lain dalam lingkungan terkontrol buatan. Lab. ini memiliki dua Biosafety Cabinet (BSC) level 2, Inkubator CO2, Freezer (-80 dan -20), Microscope, Cell Counter dan peralatan lain yang mendukung semua eksperimen.

Proteomic Lab.

Laboratorium Proteomik di MRIN dilengkapi dengan instrumentasi canggih, seperti Western Blot, HPLC, Microplate Reader, Freeze dryer dan Akta Purifier. Semua instrumen yang ada memungkinkan tim MRIN untuk melakukan dan menyediakan berbagai analisis proteomik seperti pemisahan, identifikasi, karakterisasi, dan kuantifikasi protein yang diekspresikan dalam sampel biologis.

Disposal Treatment Room.

Ruangan ini dilengkapi dengan dua unit mesin autoklaf untuk limbah dan sterilisasi bersih. Kipas buang terpasang di langit-langit untuk mendukung aliran udara dan mengeluarkan suhu tinggi dari ruangan. Selain itu juga disediakan mesin ice breaker untuk mendukung pekerjaan laboratorium MRIN dan inkubator suhu tinggi (60 derajat) di ruangan ini.

Preparation Room.

Preparation Lab adalah tempat untuk membuat semua buffer dan reagen kimia yang dibutuhkan dalam percobaan. Lab. ini dilengkapi dengan peralatan untuk menunjang pekerjaan seperti; Pengukur pH, Timbangan, Timbangan Analitik, dan Pemurni Air ELGA

Microscope Room.

Mikroskop merupakan salah satu peralatan pendukung penelitian di Mochtar Riady Institute. Mikrosop digunakan untuk mendukung penelitian kanker (kultur sel, histologi, hibridisasi in situ, dan imunohistokimia).

Researchers.

Prof. dr. Irawan Yusuf, Ph.D.

President of Mochtar Riady Institute for Nanotechnology
Prof. dr. Irawan Yusuf, Ph.D after his undergraduate from medical doctor from Hasanuddin University. In 1992, he continued the Post Doctoral at the School of Medicine, University of Hiroshima in the field of molecular and cellular cardiac electrophysiology. He has been a Lecture at Physiology Department, Faculty of Medicine, Universitas Hasanuddin, Makasar since 1986. He was appointed as a Vice Dean in 2002 and continued his career as a Dean from 2006 to 2014. His university promoted him as Professor of Physiology in 2005 He joined as a Senior Researcher at Eijkman Institute from 1995 to 2002, He had been invited as external examiner for Ph.D of Leiden University in 2007, Utrecht University in 2009, Amsterdam University in 2013, and as a Visiting Professor at Kyoto University, Japan in 2015. He was honoured with the best of Head of Study Program from Ministry of Research and Technology, Republic of Indonesia in 2009 and received Satya Lencana Karya 20 years from the Government of Republic Indonesia in 2010. He is also received Juned Pusponegro award from Indonesian Medical Association in 2012 and Ahmad Bakrie Award for Medical Category in 2013 He is appointed as Chair of Steering Committee Novartis Eijkman Hasanuddin Clinical Research Initiative which is focusing research in tuberculosis and dengue fever. He was also appointed as Chair of Ethic Committee at Mochtar Riady Institute for Nanotechnology, Member of National Research Board, National Bioethics Commission and Vice Chair of National Ethics Commission on Health Research. From 2007 to 2009 he was a Chairman of Indonesian Medical Association, and from 2009 – 2012 he was a Chairman of Indonesian Medical Colloqium. From 2008 up to know he has been involving in the Indonesian Academy of Science.

Dr. rer. nat. Ivet Suriapranata

Principal Investigator
Received her PhD degree in Biochemistry from the University of Stuttgart, Germany. Prior to joining the MRIN, she was Postdoctoral Researcher in the Division of Biological Sciences, University of California, San Diego, USA. Her research interest is Single Nucleotide Polymorphism in association with cancer development and progression.

Professor Wahyuni Lukita Atmodjo M.D., Ph.D.

Principal Investigator
Received her Ph. D degree in Medical Science from Kobe University, Kobe, Japan. She accomplished her Postdoctoral Research at Tokyo Medical and Dental University, Tokyo, Japan. She was as a research fellow in the College of Medicine, University of Arizona sponsored by Educational Commission for Foreign Medical Graduate (ECFMG), Washington DC, USA. Her main research interests are Morphological and Micro Vascular Responses due to Paracrine and Autocrine Relationship among Liver Sinusoidal Cells in the Inflammatory Process towards Cirrhosis.

Dr. rer. nat. Bustanur Rosidi

Principal Investigator
Dr.Rernat Bustanur Rosidi studied Biochemistry at Leibniz University of Hannover, Germany. After completing his PhD he joined the research group of Prof. Dr. George Iliakis at Institute for Medical Radiation Biology, University Duisburg-Essen’s Medical School in Essen Germany,as Post Doc. He then moved to Malaysia and worked as senior lecturer at University Technology Malaysia in Johor Bahru, before joined MRIN in July 2012. His research area of interest is cancer chemoprevention with focus on colorectal cancer.

Dr. John Eu-Li Wong, MBBS, FAMS, FRCP, FACP

Scientific Advisory Board Members
Dr. John Wong is Dean of the Yong Loo Lin School of Medicine at the National University of Singapore (NUS), Deputy Chief Executive of the National University Health System (NUHS) and Director of the National University Cancer Institute, Singapore (NCIS). A medical oncologist-haematologist, Dr. Wong obtained his MBBS from NUS and did his residency and fellowship at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. With research interests in the development of new drugs and treatment strategies, and differences between Asian and Caucasian cancers, Dr. Wong jointly founded the Cancer Therapeutics Research Group (CTRG), a multi-national consortium of nine institutions, and has served on the American Society of Clinical Oncology International Affairs Committee. He has been actively involved in the development of the biomedical sciences as a key pillar of Singapore’s economy, as well as the introduction of Singapore’s first academic health system, linking the National University Hospital and the National University of Singapore’s medical, dental, and nursing schools under one unified governance. Dr. Wong has initiated collaborations with leading institutions in Europe, Asia, and the U.S. He has also been involved in the expansion of the Association of Academic Health Centers into AAHC International. He serves on the International Coordinating Committee of AAHC International and organized the AAHC Inaugural Asia Pacific Meeting in Singapore in February 2009. He is a frequent invited speaker on academic medicine at international meetings such as the AAHC International Forum, the World Health Summit, and the Annual World Health Care Congress Europe.

Prof. Esther H. Chang, MD, Ph.D.

Scientific Advisory Board Members
Professor Esther H. Chang is a member of the Departments of Oncology and Otolaryngology at the Lombardi Cancer Center, Georgetown University Medical Center. Before joining Georgetown University, Dr. Chang held positions in the National Cancer Institute, as a professor in the Department of Surgery at Stanford University, and as a professor in the Departments of Pathology and Surgery at the Uniformed Services University of the Health Sciences. Dr. Chang has been a pioneer and major contributor to understanding genetic influences on both the development and suppression of cancerous tumors, as well as to understanding the tumor’s resistance to radio/chemotherapy. She was the first to identify human versions of a mouse viral oncogene and to demonstrate the role of these “ras oncogenes” in causing cancer. Her research group also was the first to demonstrate, simultaneously with another, that a mutated p53 gene inherited in a cancer-prone family plays a role in the early stages of cancer development. Recently, her research on the application of nanotechnology to cancer therapy, diagnosis and prevention was recognized in Science News Magazine as among the most promising efforts in the field. Her group also has been evaluating the combination of tumor-targeted gene therapy and more conventional radiotherapy or chemotherapy for treatment of cancers. Dr. Chang has served as a member of a number of scientific advisory boards for the National Cancer Institute, NASA, the US Military Cancer Institute, and the Department of Energy. Her scientific findings have been published in prominent journals including Nature, Science, and Cell, as well as many other leading journals. Dr. Chang also has dedicated much time to the education of graduate and medical students, and has held peer reviewed grants from the NIH for more than 20 years, without interruption.